Incyte to Present STOP-HS, TRuE-PN Trials at EADV 2025
Incyte announced that it will present new data from studies throughouts its dermatology pipeline at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, according to a press release from the manufacturer.
Among the presentations of interest (see Table ) is the 24-week Phase 3 data from the STOP-HS program, which looked at the oral, selective JAK1 inhibitor povorcitinib for moderate to severe hidradenitis suppurativa (HS). Also featured in the late-breaking sessions will be pooled data from the phase 3 TRuE-PN1 and TRuE-PN2 studies assessing ruxolitinib cream in prurigo nodularis (PN).
Incyte will also present research on vitiligo, including a phase 2 study examining vitiligo-associated hearing loss, as well as multiple posters on ruxolitinib cream’s utility, pediatric data in atopic dermatitis, and long-term safety analyses for multiple indications.
“The late-breaking data from the STOP-HS clinical trial program reinforce the potential of povorcitinib to benefit patients impacted by hidradenitis suppurativa (HS), a challenging and debilitating immunemediated dermatologic condition,” said Pablo J. Cagnoni, MD, President and Head of R&D at Incyte, said in the press release. “Data on ruxolitinib cream in new patient populations continues to demonstrate safety and efficacy in individuals with atopic dermatitis (AD), vitiligo and prurigo nodularis (PN). We look forward to advancing these studies, and to providing additional treatment options for patients.”
Table. New research from Incyte planned for presentation at EADV 2025.
Condition | Presentation |
Hidradenitis Suppurativa | Povorcitinib for Moderate to Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results |
Prurigo Nodularis | Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Pooled Results from TRuE-PN1 & PN2 |
Vitiligo | Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss (Phase 2 Trial of Povorcitinib) |
Atopic Dermatitis | Ruxolitinib Cream Demonstrated Long-Term Disease Control with Time Off Treatment in Children |
Vitiligo | Characterization of Vitiligo and Repigmentation Response by Lesion Extent and Distribution |
Vitiligo | Open-Label, Phase 2 Study of Ruxolitinib Cream in Patients With Genital Vitiligo |
Vitiligo | Ruxolitinib Cream + NB-UVB Phototherapy for Vitiligo |
Multiple Indications | Long-Term Safety of Ruxolitinib Cream in Pediatric and Adult Patients |
Source: Incyte press release, September 10, 2025.